Numinus Wellness Inc. (T:NUMI)
Business Focus: Biotechnology & Medical Research (NEC)
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Company Contact | |
| Address: | 393 Laurier Ave W MONTREAL QC H2V 2K3 |
| Tel: | N/A |
| Website: | https://numinus.com |
| IR: | See website |
| Key People | ||
| Payton Nyquvest President, Chief Executive Officer, Director | Nikhil Handa Chief Financial Officer | Michael Tan Chief Operating Officer, Director |
| Devon Christie Medical Director and Member of Clinical Advisory Council | Judy Varga Head of Laboratory Operations | Stacey Wallin Chief Strategy Officer | Evan Wood Chief Medical Officer |
| Business Overview |
| Numinus Wellness Inc. (Numinus) is a Canada-based mental health care company. The Company develops proprietary, psychedelic-centered, therapeutic products and services through its own laboratory and research and development processes. The Company operates through three segments: Clinical Research Operations, the Canadian Clinic Network, the U.S. Clinic Network. Its Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Numinus clinic network in Canada consists of Numinus Health, Mindspace, and the NCT. Numinus clinic network in the United States consists of Cedar Psychiatry Inc. (Cedar Psychiatry) and Foundations for Change Inc. (FFC). Numinus clinic network provides services including ketamine-assisted psychotherapy (KAP) for depression, transcranial magnetic stimulation (TMS), neurological care and psychotherapy and counselling by registered psychologists. |
| Financial Overview |
| For the fiscal year ended 31 August 2023, Numinus Wellness Inc revenues increased from C$6.5M to C$23.2M. Net loss decreased 33% to C$30.3M. Revenues reflect US Clinic Network segment increase from C$3M to C$16.4M, Clinical research operations segment increase from C$749K to C$3.5M, United States segment increase from C$3.5M to C$19.9M, Canada segment increase of 10% to C$3.3M. |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $33.36M as of Aug 31, 2023 |
| Annual revenue (TTM): | $23.18M as of Aug 31, 2023 |
| EBITDA (TTM): | -$24.13M as of Aug 31, 2023 |
| Net annual income (TTM): | -$30.26M as of Aug 31, 2023 |
| Free cash flow (TTM): | -$23.14M as of Aug 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 266,455,100 as of Aug 31, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.